Literature DB >> 320931

Flucytosine.

J E Bennet.   

Abstract

Flucytosine is a systemic antifungal drug that is readily absorbed from the gastrointestinal tract. The most clearly documented therapeutic effect has been in cryptococcosis, candidiasis, and chromomycosis. An important limitation of the use of flucytosine in all three diseases has been drug resistance arising during therapy. The addition of low-dose, intravenous amphotericin B to flucytosine therapy of cryptococcosis has appeared to decrease the frequency of secondary flucytosine resistance. In addition, the two drugs have an additive or slightly synergistic effect against flucytosine susceptible isolates of Cryptococcus and Candida. The combination is probably the treatment of choice in cryptococcal meningitis and offers promise in the therapy of systemic candidiasis and nonmeningeal cryptococcosis.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 320931     DOI: 10.7326/0003-4819-86-3-319

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  46 in total

Review 1.  Pharmacokinetics of antifungal agents in children.

Authors:  Kevin Watt; Daniel K Benjamin; Michael Cohen-Wolkowiez
Journal:  Early Hum Dev       Date:  2011-02-01       Impact factor: 2.079

Review 2.  Antifungal therapy: from amphotericin B to present.

Authors:  W E Dismukes
Journal:  Trans Am Clin Climatol Assoc       Date:  1993

Review 3.  Adverse drug reactions to systemic antifungals. Prevention and management.

Authors:  J R Perfect; M H Lindsay; R H Drew
Journal:  Drug Saf       Date:  1992 Sep-Oct       Impact factor: 5.606

4.  Systemic antifungal agents.

Authors:  L O Gentry
Journal:  Tex Heart Inst J       Date:  1990

5.  Cryptococcosis in AIDS patients: observations concerning CNS involvement.

Authors:  T Weinke; G Rögler; C Sixt; B de Matos-Marques; H D Pohle; F Staib; M Seibold
Journal:  J Neurol       Date:  1989-01       Impact factor: 4.849

6.  The gene encoding phosphoribosylaminoimidazole carboxylase (ADE2) is essential for growth of Cryptococcus neoformans in cerebrospinal fluid.

Authors:  J R Perfect; D L Toffaletti; T H Rude
Journal:  Infect Immun       Date:  1993-10       Impact factor: 3.441

7.  Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans: possible factor in 5-fluorocytosine clinical toxicity.

Authors:  R B Diasio; D E Lakings; J E Bennett
Journal:  Antimicrob Agents Chemother       Date:  1978-12       Impact factor: 5.191

8.  Interactions among amphotericin B, 5-fluorocytosine, ketoconazole, and miconazole against pathogenic fungi in vitro.

Authors:  F C Odds
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

Review 9.  Antifungal agents used in systemic mycoses. Activity and therapeutic use.

Authors:  J R Graybill; P C Craven
Journal:  Drugs       Date:  1983-01       Impact factor: 9.546

10.  Fungal retinitis: a case of Torulopsis glabrata infection treated with miconazole.

Authors:  R B Fitzsimons; M D Nicholls; F A Billson; T I Robertson; P Hersey
Journal:  Br J Ophthalmol       Date:  1980-09       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.